LEHI, Utah and LOUISVILLE, Ky., Nov. 26, 2024 /PRNewswire/ -- Waystar Holding Corp. (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins will speak at two upcoming investor conferences:
Waystar will provide live webcasts of both events on its Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will also be available on the site after the events.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 18 of 22 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 5 billion healthcare payment transactions, including over $1.2 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$36.87 |
Daily Change: | 0.16 0.44 |
Daily Volume: | 352,924 |
Market Cap: | US$6.340B |
November 06, 2024 September 24, 2024 August 07, 2024 |
Recursion Pharmaceuticals is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB